Aclaris Therapeutics, Inc. - Common Stock, $0.00001 par value (ACRS) Institutional Ownership

13F Institutional Holders and Ownership History from Q4 2015 to Q4 2025

Type / Class
Equity / Common Stock, $0.00001 par value
Symbol
ACRS on Nasdaq
Shares outstanding
120,020,745
Price per share
$3.01
All holders as of 30 Sep 2025
Q3 2025
Total 13F shares
85,675,311
Total reported value
$162,782,120
% of total 13F portfolios
0%
Share change
-6,186,333
Value change
-$11,317,620
Number of holders
103
Price from insider filings
$3.01
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of Aclaris Therapeutics, Inc. - Common Stock, $0.00001 par value (ACRS) based on Schedule 13D/G filings

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
BML Investment Partners, L.P. 13% $21,802,500 14,250,000 BML Investment Partners, L.P. 31 Dec 2024
Bonita Biotech (HK) Ltd 9.4% $33,944,003 11,281,950 Biosion, Inc. 09 Dec 2025
VANGUARD GROUP INC 6.2% +31% $10,192,956 +$2,588,468 6,662,063 +34% The Vanguard Group 30 Jun 2025
BlackRock, Inc. 5.1% $8,371,718 5,471,711 BlackRock, Inc. 30 Jun 2025
Adage Capital Management, L.P. 4.9% -34% $10,028,474 -$5,554,080 5,278,144 -36% Adage Capital Management, L.P. 30 Sep 2025
Rock Springs Capital Management LP 4.7% $7,720,853 5,046,309 Rock Springs Capital Management LP 31 Mar 2025
MILLENNIUM MANAGEMENT LLC 3.5% -32% $5,871,191 -$2,609,810 3,837,380 -31% Millennium Management LLC 30 Jun 2025

As of 30 Sep 2025, 103 institutional investors reported holding 85,675,311 shares of Aclaris Therapeutics, Inc. - Common Stock, $0.00001 par value (ACRS). This represents 71% of the company’s total 120,020,745 outstanding shares.

Top 25 Institutional Shareholders

The largest institutional shareholders of Aclaris Therapeutics, Inc. - Common Stock, $0.00001 par value (ACRS) together control 65% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.

Institution Ownership % Shares Held Share Change % Portfolio % Holdings Value
BML Capital Management, LLC 12% 14,250,000 0% 25% $27,075,000
Vivo Capital, LLC 7.4% 8,888,888 0% 1.4% $16,888,887
VANGUARD GROUP INC 5.4% 6,515,458 -2.2% 0% $12,379,370
BlackRock, Inc. 4.7% 5,691,352 +3.2% 0% $10,813,569
ADAGE CAPITAL PARTNERS GP, L.L.C. 4.4% 5,278,144 -45% 0.02% $10,028,474
Rock Springs Capital Management LP 3.8% 4,609,309 -3.4% 0.51% $8,757,687
MORGAN STANLEY 3.4% 4,077,246 +15% 0% $7,746,768
Decheng Capital LLC 3.4% 4,041,736 0% 1.3% $7,679,298
GEODE CAPITAL MANAGEMENT, LLC 2% 2,389,531 -3.1% 0% $4,541,475
D. E. Shaw & Co., Inc. 2% 2,373,226 -15% 0% $4,509,129
ACADIAN ASSET MANAGEMENT LLC 1.9% 2,327,019 -4.4% 0.01% $4,417,000
MARSHALL WACE, LLP 1.4% 1,718,130 -25% 0% $3,264,447
RENAISSANCE TECHNOLOGIES LLC 1.3% 1,619,731 +11% 0% $3,077,489
Palo Alto Investors LP 1.3% 1,566,840 +13% 0.55% $2,976,996
MILLENNIUM MANAGEMENT LLC 1.3% 1,554,458 -59% 0% $2,953,470
Logos Global Management LP 1.2% 1,500,000 -19% 0.28% $2,850,000
CITADEL ADVISORS LLC 1.2% 1,432,677 +25% 0% $2,722,086
AMERIPRISE FINANCIAL INC 1.1% 1,277,817 0% $2,427,852
Bollard Group LLC 1% 1,225,476 -9.4% 0.06% $2,328,000
STATE STREET CORP 0.93% 1,113,146 +11% 0% $2,114,977
Connor, Clark & Lunn Investment Management Ltd. 0.89% 1,067,656 +34% 0.01% $2,028,546
Aldebaran Capital, LLC 0.82% 987,698 -0.6% 1.7% $1,876,626
GOLDMAN SACHS GROUP INC 0.8% 956,051 +511% 0% $1,816,497
DEUTSCHE BANK AG\ 0.77% 923,313 -8.3% 0% $1,754,295
JPMORGAN CHASE & CO 0.63% 758,576 +22% 0% $1,441,294

Institutional Holders of Aclaris Therapeutics, Inc. - Common Stock, $0.00001 par value (ACRS) across Reporting Periods

Period Reported Shares, Excl. Options Value, Excl. Options Value Change Price (Median) Investors
2025 Q4 188,306 $566,378 -$18,963 $3.01 5
2025 Q3 85,675,311 $162,782,120 -$11,317,620 $1.90 103
2025 Q2 91,862,934 $130,444,350 -$2,093,222 $1.42 96
2025 Q1 92,164,636 $141,009,418 +$2,108,833 $1.53 106
2024 Q4 87,477,187 $216,984,078 +$93,724,731 $2.48 97
2024 Q3 50,891,008 $58,523,068 -$1,741,586 $1.15 76
2024 Q2 52,847,546 $58,128,663 -$1,611,720 $1.10 92
2024 Q1 54,384,737 $67,434,778 -$3,190,228 $1.24 92
2023 Q4 18,219 $19,130 -$176,266 $1.05 1
2023 Q3 70,071,718 $479,972,880 -$28,108,482 $6.85 136
2023 Q2 71,014,841 $736,442,966 +$5,835,776 $10.37 131
2023 Q1 71,610,627 $579,301,984 +$19,731,487 $8.09 148
2022 Q4 65,793,840 $1,036,264,594 -$2,518,432 $15.75 125
2022 Q3 63,567,901 $1,000,532,702 +$4,193,209 $15.74 122
2022 Q2 63,226,445 $882,716,693 +$55,563,528 $13.96 109
2022 Q1 59,101,299 $1,018,565,185 +$65,457,217 $17.24 105
2021 Q4 55,941,179 $813,375,981 -$38,630,265 $14.54 129
2021 Q3 56,753,671 $1,021,573,424 +$15,134,678 $18.00 125
2021 Q2 55,979,011 $982,955,407 +$173,991,985 $17.56 127
2021 Q1 45,417,666 $1,144,775,972 +$405,403,175 $25.20 95
2020 Q4 30,428,993 $196,854,000 +$26,740,927 $6.47 77
2020 Q3 24,251,145 $62,327,000 -$3,890,419 $2.57 50
2020 Q2 28,451,383 $46,091,261 -$5,395,742 $1.62 54
2020 Q1 28,795,595 $29,946,056 +$5,248,294 $1.04 58
2019 Q4 28,116,392 $53,134,600 +$4,000,368 $1.89 69
2019 Q3 25,908,655 $27,980,961 -$18,805,284 $1.08 68
2019 Q2 32,560,086 $71,276,747 -$14,438,755 $2.19 78
2019 Q1 37,383,948 $223,931,462 -$10,842,778 $5.99 87
2018 Q4 38,892,074 $287,388,553 +$36,705,596 $7.39 91
2018 Q3 29,075,103 $422,221,871 -$34,372,609 $14.52 77
2018 Q2 30,988,731 $618,764,703 +$11,593,043 $19.97 90
2018 Q1 30,152,933 $528,297,405 +$32,321,461 $17.52 96
2017 Q4 28,495,106 $702,048,266 -$5,456,626 $24.66 99
2017 Q3 28,502,589 $734,504,527 +$71,530,796 $25.81 102
2017 Q2 25,609,895 $694,432,125 +$23,959,488 $27.12 101
2017 Q1 23,619,007 $703,088,110 +$73,933,651 $29.82 109
2016 Q4 21,241,619 $576,501,455 +$94,863,078 $27.14 99
2016 Q3 15,510,238 $396,499,578 +$5,204,097 $25.61 59
2016 Q2 15,355,135 $282,506,339 +$12,193,506 $18.47 47
2016 Q1 14,603,573 $276,722,000 +$2,033,651 $18.95 33
2015 Q4 10,287,034 $277,130,982 +$208,041,927 $26.94 31